Compare 8x8 Inc (EGHT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs Recursion Pharmaceuticals Inc — how do they compare? 8x8 Inc trades at $2 (market cap $309.09M), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 5.9× 8x8 Inc's market cap, and 8x8 Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| EGHT | RXRX | |
|---|---|---|
Market Cap | $309.09M | $1.81B |
Sector | Technology | Health |
52-Week High | $2.76 | $6.79 |
52-Week Low | $1.59 | $2.84 |
Enterprise Value | $576.02M | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $1.995, down 10.94% in the past 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported record service revenue in Q1 2027, beating earnings estimates for the fourth consecutive quarter. Recent news highlights AI expansion and a new partner program aimed at customer growth.
The outlook is mixed: strong revenue growth and AI adoption offer upside, but high P/E of 71.33 and negative net income in 2025 pose risks. Analyst consensus is a buy with a $3.13 target, though debt levels and profitability challenges require monitoring for sustained investor confidence.
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
